Vicodin vex: DEA tightens restrictions on hydrocodone combos

From NeurologyWire

On Friday the US Drug Enforcement Administration (DEA) will move hydrocodone combination products (HCPs) from Schedule III to the more-restrictive Schedule II.Pure hydrocodone drugs have been listed as Schedule II drugs since the creation of the list in 1971. But hydrocodone-combination products (HCPs)those made with specified amounts of other ther...

Login to read story

Wednesday, September 17, 2014

Show last days of articles

Pre-injury migraines play no effect in study's measure of po...

From NeurologyWire

Findings from a new study did not indicate that athletes with a history of preinjury migraine headaches demonstrate greater neurocognitive declines fo...Full story

Program launches to "optimize treatment and understand progr...

From NeurologyWire

EMD Serono, Inc., a subsidiary of Merck KGaA, and the Accelerated Cure Project for Multiple Sclerosis have initiated a founding sponsor agreement to h...Full story

Tuesday, September 16, 2014

FDA approves Movantik for opioid-induced constipation

From NeurologyWire

The U.S. Food and Drug Administration has approved Movantik (naloxegol), an oral treatment for opioid-induced constipation in adults with chronic non-...Full story

Friday, September 12, 2014

Few Parkinson's patients suffer from malnutrition, yet almos...

From NeurologyWire

Patients with Parkinson's disease (PD) can experience difficulties with food preparation and ingestion, which could contribute to poor nutrition and p...Full story

Thursday, September 11, 2014

Plegridy (Peginterferon Beta-1a) Two-Year Data Confirm Maint...

From NeurologyWire

Today Biogen Idec (NASDAQ: BIIB) announced new data from the second year of its Phase 3 ADVANCE clinical trial that show the positive treatment effect...Full story

Lemtrada (alemtuzumab) sees positive interim results

From NeurologyWire

Genzyme, a Sanofi company, presented today positive interim results from the second year of the extension study of Lemtrada (alemtuzumab) for multiple...Full story

Wednesday, September 10, 2014

FDA green-lights wrist device for assessment of Parkinson's ...

From NeurologyWire

Global Kinetics Corporation said that the U.S. Food and Drug Administration (FDA) has cleared the marketing of the company's Personal KinetiGraph (PKG...Full story

Tuesday, September 09, 2014

Parkinson's Disease Foundation Plans Series of Online Semina...

From NeurologyWire

The Parkinson's Disease Foundation is planning its sixth series of PD ExpertBriefings, free interactive seminars presented by leaders in Parkinson's d...Full story

Monday, September 08, 2014

Broken signals lead to neurodegeneration

From NeurologyWire

Researchers from the Riken Brain Science Institute in Japan, in collaboration with Juntendo University and the Japan Science and Technology Agency, ha...Full story

Fishy proposition for seizure treatment

From NeurologyWire

A new study by researchers at the UCLA School of Medicine now suggests that for epilepsy patients, improvement might come in the form of a few capsule...Full story

Friday, September 05, 2014

Potassium-rich foods cut stroke, death risks among older wom...

From NeurologyWire

Postmenopausal women who eat foods higher in potassium are less likely to have strokes and die than women who eat less potassium-rich foods, according...Full story

Thursday, September 04, 2014

National Survey Seeks To Shed Light On Impact Of Rare Seizur...

From NeurologyWire

A new landmark U.S. seizure disorder survey is being commissioned by the Epilepsy Foundation (EF) to shed light on the burden of illness associated wi...Full story

Wednesday, September 03, 2014

Child-parent bedsharing impairs sleep quality in study

From NeurologyWire

Bedsharing reduce infants sleep duration and leads to a higher number of awakenings, suggests a new study in Journal of Developmental and Behavioral P...Full story

NICO BrainPath Medical Device for Safely Accessing the Brain...

From NeurologyWire

Indianapolis medical device maker NICO Corporation was recognized with the Indiana Innovation Award for its BrainPath technology used for safely and a...Full story

Tuesday, September 02, 2014

Nuplazid (pimavanserin) receives breakthrough therapy design...

From NeurologyWire

Acadia Pharmaceuticals Inc. said the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Nuplazid (pimavanserin) f...Full story